| [1] |
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61(1): 2200879. doi: 10.1183/13993003.00879-2022.
|
| [2] |
Hu P, Xu Y, Jiang Y, et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11[J]. Eur J Pharmacol, 2022, 928:175093. doi: 10.1016/j.ejphar.2022.175093.
|
| [3] |
Fang W, Xie S, Deng W. Ferroptosis mechanisms and regulations in cardiovascular diseases in the past, present, and future[J]. Cell Biol Toxicol, 2024, 40(1): 17. doi: 10.1007/s10565-024-09853-w.
pmid: 38509409
|
| [4] |
Li X, Tan J, Wan J, et al. Cell death in pulmonary arterial hypertension[J]. Int J Med Sci, 2024, 21(10): 1840-1851. doi: 10.7150/ijms.93902.
pmid: 39113898
|
| [5] |
Chen Y, Li X, Wang S, et al. Targeting iron metabolism and ferroptosis as novel therapeutic approaches in cardiovascular diseases[J]. Nutrients, 2023, 15(3): doi: 10.3390/nu15030591.
|
| [6] |
吴楠, 杨涛, 胡玉原, 等. 铁稳态、铁死亡与心血管疾病[J]. 临床与病理杂志, 2024, 44(2):295-306. doi: 10.11817/j.issn.2095-6959.2024.240119.
|
| [7] |
Li J, Cao F, Yin HL, et al. Ferroptosis: Past, present and future[J]. Cell Death Dis, 2020, 11(2): 88. doi: 10.1038/s41419-020-2298-2.
pmid: 32015325
|
| [8] |
Protchenko O, Baratz E, Jadhav S, et al. Iron Chaperone poly rc binding protein 1 protects mouse liver from lipid peroxidation and steatosis[J]. Hepatology, 2021, 73(3): 1176-1193. doi: 10.1002/hep.31328.
|
| [9] |
Qin Y, Qiao Y, Wang D, et al. Ferritinophagy and ferroptosis in cardiovascular disease: Mechanisms and potential applications[J]. Biomed Pharmacother, 2021, 141(111872). doi: 10.1016/j.biopha.2021.111872.
|
| [10] |
Zhang Y, Xin L, Xiang M, et al. The molecular mechanisms of ferroptosis and its role in cardiovascular disease[J]. Biomed Pharmacother, 2022, 145:112423. doi: 10.1016/j.biopha.2021.112423.
|
| [11] |
Su LJ, Zhang JH, Gomez H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis[J]. Oxid Med Cell Longev, 2019, 2019:5080843. doi: 10.1155/2019/5080843.
|
| [12] |
Xie LH, Fefelova N, Pamarthi SH, et al. Molecular mechanisms of ferroptosis and relevance to cardiovascular disease[J]. Cells, 2022, 11(17): doi: 10.3390/cells11172726.
|
| [13] |
Zhang F, Liu H. Identification of ferroptosis-associated genes exhibiting altered expression in pulmonary arterial hypertension[J]. Math Biosci Eng, 2021, 18(6): 7619-7630. doi: 10.3934/mbe.2021377.
pmid: 34814266
|
| [14] |
Kazmirczak F, Vogel NT, Prisco SZ, et al. Ferroptosis integrates mitochondrial derangements and pathological inflammation to promote pulmonary hypertension[J]. 2024, 23:2023.01.19.524721.doi: 10.1101/2023.01.19.524721.
|
| [15] |
Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation[J]. Cell Death Dis, 2019, 10(11): 822. doi: 10.1038/s41419-019-2064-5.
pmid: 31659150
|
| [16] |
Xie SS, Deng Y, Guo SL, et al. Endothelial cell ferroptosis mediates monocrotaline-induced pulmonary hypertension in rats by modulating NLRP3 inflammasome activation[J]. Sci Rep, 2022, 12(1): 3056. doi: 10.1038/s41598-022-06848-7.
|
| [17] |
Liao J, Xie SS, Deng Y, et al. PRDX6-mediated pulmonary artery endothelial cell ferroptosis contributes to monocrotaline-induced pulmonary hypertension[J]. Microvasc Res, 2023, 146:104471. doi: 10.1016/j.mvr.2022.104471.
|
| [18] |
Ahola S, Langer T. Ferroptosis in mitochondrial cardiomyopathy[J]. Trends Cell Biol, 2024, 34(2): 150-160. doi: 10.1016/j.tcb.2023.06.002.
|
| [19] |
Kazmirczak F, Vogel NT, Prisco SZ, et al. Ferroptosis mediated inflammation promotes pulmonary hypertension[J]. Circ Res, 2024, 135(11):1067-1083. doi: 10.1161/circresaha.123.324138.
pmid: 39421926
|
| [20] |
Song J, Chen Y, Chen Y, et al. Ferrostatin-1 blunts right ventricular hypertrophy and dysfunction in pulmonary arterial hypertension by suppressing the HMOX1/GSH signaling[J]. J Cardiovasc Transl Res, 2024, 17(1): 183-196. doi: 10.1007/s12265-023-10423-4.
|
| [21] |
Chen T, Ding L, Zhao M, et al. Recent advances in the potential effects of natural products from traditional Chinese medicine against respiratory diseases targeting ferroptosis[J]. Chin Med, 2024, 19(1): 49. doi: 10.1186/s13020-024-00918-w.
|
| [22] |
Lv J, Shi S, Fu Z, et al. Exploring the inflammation-related mechanisms of Lingguizhugan decoction on right ventricular remodeling secondary to pulmonary arterial hypertension based on integrated strategy using UPLC-HRMS, systems biology approach, and experimental validation[J]. Phytomedicine, 2024, 132:155879. doi: 10.1016/j.phymed.2024.155879.
|
| [23] |
Che H, Yi J, Zhao X, et al. Characterization of PKCα-rutin interactions and their application as a treatment strategy for pulmonary arterial hypertension by inhibiting ferroptosis[J]. Food Funct, 2024, 15(2): 779-793. doi: 10.1039/d3fo01306e.
pmid: 38126185
|
| [24] |
Chen F, Wang H, Yan J, et al. Grape seed proanthocyanidin reverses pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension by down-regulating HSP70[J]. Biomed Pharmacother, 2018, 101(123-128). doi: 10.1016/j.biopha.2018.02.037.
|
| [25] |
Wang L, Liu C, Wang L, et al. Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis[J]. Eur J Pharmacol, 2023, 944:175516. doi: 10.1016/j.ejphar.2023.175516.
|
)
